Lucis Raises $20M for AI Preventive Health Platform

Jan de Vries · 2026-05-26

### What is Lucis? Lucis is a Paris-based preventive health platform that uses blood biomarker analysis and AI to deliver personalized, science-based health recommendations. The company just raised $20 million (€17.1 million) in Series A funding. That's a big deal for the European health tech scene. ### The Funding Round The round was led by Singular, with participation from General Catalyst, Y Combinator, and several high-profile angels. This follows Lucis's $8.5 million (€7.2 million) Seed round in December 2025. Total funding now stands at $28 million (€24 million). That's a lot of confidence from investors. ### The Problem They're Solving Maxime Berthelot, co-founder and CEO, put it bluntly: "We've seen the devastating impact of late-stage diagnosis first-hand. The science is already there; what's missing is a system designed to act before symptoms appear." He's right. Most healthcare systems are reactive, not proactive. You wait until you're sick, then you get treated. Lucis wants to flip that model. ### How It Works Founded in 2025 by Maxime Berthelot and Baptiste Debever, Lucis gives you a comprehensive, data-driven view of your health. The platform analyzes more than 110 blood biomarkers across key systems, including: - Metabolic health - Hormones - Cardiovascular risk - Inflammation - Nutrient levels These results feed into an AI-driven health companion app. The app uses longitudinal data and medical context to provide personalized advice on nutrition, supplements, lifestyle adjustments, and follow-up testing. The recommendations get refined as new data comes in and are reviewed by physicians. So it's not just data dump; it's actionable guidance. ### Early Results Are Impressive Lucis has over 10,000 users now. Early data shows meaningful health outcomes. Among users who completed a six-month follow-up, 75% improved at least three biomarkers without medication. More than 80% opted to retest, which suggests people are actually sticking with it. Here's a shocking stat: during initial testing, 99.9% of users had at least one biomarker outside the optimal range, often without knowing it. That's almost everyone. It shows how potential health risks can go completely unnoticed without regular monitoring. ### Expansion Plans Since launching in 2025, Lucis has expanded to France, the UK, Ireland, and Portugal. They've conducted more than one million biomarker tests. They've also built a community of thousands and formed partnerships with lab groups like Eurofins and Randox. With the fresh funding, they plan to expand into Spain, Germany, and Italy by the end of 2026. They'll keep investing in personalization, longitudinal monitoring, and clinical safety. ### The Team Behind It Lucis currently has a team of 20 people across engineering, clinical, growth, and operations. They also have a medical board and a network of over 10 physicians providing clinical oversight. That's lean but focused. Jeremy Uzan, co-founder and GP at Singular, summed it up well: "Europe's preventive health category will be won by platforms that unite clinical credibility with AI at scale. Lucis has moved with remarkable velocity, reaching 10,000 users in under a year, delivering measurable outcomes and building a compounding data advantage that sets the standard for the category." ### Why This Matters Healthcare is broken in a lot of ways. We wait for people to get sick, then spend a fortune treating them. Lucis is trying to make prevention the default, not a privilege. That's a shift worth paying attention to, especially for anyone interested in the future of health tech and EU startup news. ### Bottom Line Lucis is a classic example of a European startup using AI to solve a real, systemic problem. They have strong investor backing, early traction, and a clear vision. If they can keep executing, they could become a major player in preventive health. And that's good news for everyone.